• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌的外科治疗。

Surgery for cholangiocarcinoma.

机构信息

Department of Surgery, Oncology and Gastroenterology, Hepatobiliary Surgery and Liver Transplantation Unit, Padova University Hospital, Padova, Italy.

Department of General & Digestive Surgery, Institut de Malalties Digestives I Metabòliques (IMDiM), Hospital Clínic, University of Barcelona, Spain.

出版信息

Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089.

DOI:10.1111/liv.14089
PMID:30843343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6563077/
Abstract

Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. For both perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA), 5-year overall survival of about 30% has been reported in large series. This review addresses several challenges in surgical management of cholangiocarcinoma. The first challenge is diagnosis: a biopsy is typically avoided because of the risk of seeding metastases and the low yield of a brush of the bile duct. However, about 15% of patients with suspected pCCA are found to have a benign diagnosis after resection. The second challenge is staging; even with the best preoperative imaging, a substantial percentage of patients has occult metastatic disease detected at staging laparoscopy or early recurrence after resection. The third challenge is an adequate volume and function of the future liver remnant, which may require preoperative biliary drainage and portal vein embolization. The fourth challenge is a complete resection: a positive bile duct margin is not uncommon because the microscopic biliary extent of disease may be more extensive than perceived on imaging. The fifth challenge is the high post-operative mortality that has decreased in very high volume Asian centres, but remains about 10% in many Western referral centres. The sixth challenge is that even after a complete resection most patients develop recurrent disease. Recent randomized controlled trials found conflicting results regarding the benefit of adjuvant chemotherapy. The final challenge is to determine which patients with cholangiocarcinoma should undergo liver transplantation rather than resection.

摘要

手术切除是胆管癌患者唯一有治愈可能的治疗方法。对于肝门部胆管癌(pCCA)和肝内胆管癌(iCCA),在大型系列研究中,约有 30%的患者报告了 5 年总生存率。这篇综述探讨了胆管癌手术治疗中的几个挑战。第一个挑战是诊断:由于种植转移的风险和胆管刷取的低产量,通常避免进行活检。然而,约 15%的疑似 pCCA 患者在切除后被发现诊断为良性。第二个挑战是分期;即使术前影像学检查最好,仍有相当一部分患者在分期腹腔镜检查或切除后早期复发时发现隐匿性转移疾病。第三个挑战是未来肝剩余部分的足够体积和功能,这可能需要术前胆道引流和门静脉栓塞。第四个挑战是完整切除:胆管边缘阳性并不少见,因为疾病的微观胆管范围可能比影像学上观察到的更广泛。第五个挑战是高术后死亡率,在高容量的亚洲中心有所下降,但在许多西方转诊中心仍约为 10%。第六个挑战是,即使进行了完整切除,大多数患者仍会出现复发性疾病。最近的随机对照试验发现辅助化疗的益处存在矛盾的结果。最后一个挑战是确定哪些胆管癌患者应该进行肝移植而不是切除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/477d/6563077/932c4c39dac7/LIV-39-143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/477d/6563077/932c4c39dac7/LIV-39-143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/477d/6563077/932c4c39dac7/LIV-39-143-g001.jpg

相似文献

1
Surgery for cholangiocarcinoma.胆管癌的外科治疗。
Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089.
2
Challenges of surgical management of intrahepatic cholangiocarcinoma.肝内胆管细胞癌的外科治疗挑战。
Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):671-681. doi: 10.1080/17474124.2018.1489229. Epub 2018 Jun 27.
3
Liver resection and transplantation for intrahepatic cholangiocarcinoma.肝切除术和肝移植治疗肝内胆管细胞癌。
J Hepatol. 2020 Feb;72(2):364-377. doi: 10.1016/j.jhep.2019.11.020.
4
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.新时代肝门部胆管癌的外科治疗: 来自首尔峨山医院的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
5
The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.肝门部和肝内胆管细胞癌中淋巴管侵犯和淋巴结转移的预后作用。
Eur J Surg Oncol. 2019 Aug;45(8):1468-1478. doi: 10.1016/j.ejso.2019.04.019. Epub 2019 Apr 25.
6
Evolution of surgery for Klatskin tumor demonstrates improved outcome: a single center analysis.肝门部胆管癌手术的进展显示预后改善:一项单中心分析
Tumori. 2014 Nov-Dec;100(6):e250-6. doi: 10.1700/1778.19288.
7
[Surgical therapy of hilar cholangiocarcinoma].[肝门部胆管癌的外科治疗]
Chirurg. 2006 Apr;77(4):325-34. doi: 10.1007/s00104-006-1177-4.
8
Perihilar cholangiocarcinoma: a surgeon's viewpoint on current topics.肝门部胆管癌:外科医生视角下的当前热点问题。
J Gastroenterol. 2012 Nov;47(11):1165-76. doi: 10.1007/s00535-012-0628-6. Epub 2012 Jul 31.
9
Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives.肝内胆管细胞癌:可切除性的局限性、当前的手术概念和未来的观点。
Eur J Surg Oncol. 2020 May;46(5):740-746. doi: 10.1016/j.ejso.2020.01.028. Epub 2020 Jan 23.
10
An assessment of risk factors for recurrence and survival for patients undergoing liver resection for intrahepatic cholangiocarcinoma.评估行肝切除术治疗肝内胆管细胞癌患者的复发和生存的风险因素。
Eur J Gastroenterol Hepatol. 2024 Jun 1;36(6):766-774. doi: 10.1097/MEG.0000000000002761. Epub 2024 Apr 24.

引用本文的文献

1
Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma.白蛋白-胆红素(ALBI)和血小板-ALBI(PALBI)分级:胆管细胞癌的新型预后因素。
In Vivo. 2025 Sep-Oct;39(5):2976-2985. doi: 10.21873/invivo.14098.
2
Endobiliary Radiofrequency Ablation for Hepato-Biliary Diseases: A Narrative Review.肝内胆管射频消融治疗肝胆疾病:一项叙述性综述
Diseases. 2025 Aug 21;13(8):273. doi: 10.3390/diseases13080273.
3
Applications of 3D models in cholangiocarcinoma.3D模型在胆管癌中的应用。

本文引用的文献

1
Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma.复发性肝内胆管癌的手术切除
World J Surg. 2019 Apr;43(4):1105-1116. doi: 10.1007/s00268-018-04876-x.
2
Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma.肿瘤多结节性对肝内胆管癌的预后影响。
J Gastrointest Surg. 2019 Sep;23(9):1801-1809. doi: 10.1007/s11605-018-4052-y. Epub 2018 Nov 26.
3
Perioperative and Long-Term Outcomes of Laparoscopic Versus Open Lymphadenectomy for Biliary Tumors: A Propensity-Score-Based, Case-Matched Analysis.
Front Oncol. 2025 Jul 31;15:1598552. doi: 10.3389/fonc.2025.1598552. eCollection 2025.
4
Minimally Invasive Surgery for Perihilar Cholangiocarcinoma-A Review of the Current Literature.肝门部胆管癌的微创手术——当前文献综述
J Clin Med. 2025 May 27;14(11):3748. doi: 10.3390/jcm14113748.
5
Stereotactic Body Radiation Therapy in Advanced Intrahepatic Cholangiocarcinoma: Real-world Outcomes from an Indian Cohort.立体定向体部放射治疗在晚期肝内胆管癌中的应用:来自印度队列的真实世界结果
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102584. doi: 10.1016/j.jceh.2025.102584. Epub 2025 Apr 28.
6
NCAPG2 is a diagnostic biomarker associated with immune infiltration in cholangiocarcinoma.NCAPG2是一种与胆管癌免疫浸润相关的诊断生物标志物。
Discov Oncol. 2025 May 30;16(1):968. doi: 10.1007/s12672-025-02809-4.
7
Interobserver variability in lymph node evaluation with endoscopic ultrasonography in cholangiocarcinoma.胆管癌内镜超声检查中淋巴结评估的观察者间变异性
Endosc Int Open. 2025 May 12;13:a25775449. doi: 10.1055/a-2577-5449. eCollection 2025.
8
Primary percutaneous stenting above the ampulla versus endoscopic drainage for unresectable malignant hilar biliary obstruction (TESLA RCT): study protocol for a multicenter randomized controlled trial.壶腹上方原发性经皮支架置入术与内镜引流术治疗不可切除性恶性肝门部胆管梗阻的比较(TESLA随机对照试验):一项多中心随机对照试验的研究方案
BMC Cancer. 2025 May 9;25(1):849. doi: 10.1186/s12885-025-14158-0.
9
Short- and long-term outcomes of laparoscopic versus open resection of perihilar cholangiocarcinoma: a propensity score-based analysis.腹腔镜与开腹手术切除肝门部胆管癌的短期和长期预后:一项基于倾向评分的分析
Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):207-221. doi: 10.21037/hbsn-23-680. Epub 2024 Aug 12.
10
Western and Eastern experience in treating perihilar cholangiocarcinoma: retrospective bi-centre study.东西方治疗肝门部胆管癌的经验:回顾性双中心研究
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zraf019.
腹腔镜与开腹淋巴结清扫术治疗胆道肿瘤的围手术期和长期疗效:基于倾向评分匹配的病例对照分析。
Ann Surg Oncol. 2019 Feb;26(2):564-575. doi: 10.1245/s10434-018-6811-0. Epub 2018 Oct 1.
4
Surgical resection of lymph node positive intrahepatic cholangiocarcinoma may not improve survival.对淋巴结阳性的肝内胆管癌进行手术切除可能无法提高生存率。
HPB (Oxford). 2019 Feb;21(2):235-241. doi: 10.1016/j.hpb.2018.08.006. Epub 2018 Sep 28.
5
Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial.内镜与经皮胆道引流治疗可切除肝门部胆管癌患者的效果比较:一项多中心随机对照试验。
Lancet Gastroenterol Hepatol. 2018 Oct;3(10):681-690. doi: 10.1016/S2468-1253(18)30234-6. Epub 2018 Aug 17.
6
Patterns of Distribution of Hepatic Nodules (Single, Satellites or Multifocal) in Intrahepatic Cholangiocarcinoma: Prognostic Impact After Surgery.肝内胆管细胞癌中单发性、卫星灶或多灶性肝结节分布模式:手术治疗后的预后影响。
Ann Surg Oncol. 2018 Nov;25(12):3719-3727. doi: 10.1245/s10434-018-6669-1. Epub 2018 Aug 7.
7
Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma.不可逆电穿孔治疗晚期高位胆管癌所致梗阻性黄疸的安全性和有效性。
HPB (Oxford). 2018 Nov;20(11):1092-1097. doi: 10.1016/j.hpb.2018.06.1806. Epub 2018 Jul 26.
8
10th Anniversary of ALPPS-Lessons Learned and quo Vadis.ALPPS 无辅助十年历程:经验与展望。
Ann Surg. 2019 Jan;269(1):114-119. doi: 10.1097/SLA.0000000000002797.
9
IgG4-Associated Cholangitis in Patients Resected for Presumed Perihilar Cholangiocarcinoma: a 30-Year Tertiary Care Experience.患者因疑似肝门部胆管癌切除术后 IgG4 相关胆管炎:30 年的三级保健经验。
Am J Gastroenterol. 2018 May;113(5):765-772. doi: 10.1038/s41395-018-0036-5. Epub 2018 Mar 16.
10
Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.根治性手术后肝门部胆管癌早期复发的定义:来自美国肝外胆管恶性肿瘤联盟的多机构研究
World J Surg. 2018 Sep;42(9):2919-2929. doi: 10.1007/s00268-018-4530-0.